Parasite | Eso | Sto | Cancer | ESD
001 | 101 | 201 | 301 | 401 | 501 | 601 | 701 | 801 | 901 | 1000
°¥¼ö·Ï ¾È ÁÁ¾ÆÁö´Â ȯÀÚ°¡ ÀÖ½À´Ï´Ù. Áúº´ »óÅ°¡ ±Þ°ÝÈ÷ ³ªºüÁø´Ù´Â Àǹ̴ ¾Æ´Ï°í, ȯÀÚÀÔÀå¿¡¼ Áø´Ü°ú Ä¡·á°¡ Á¡Â÷ ½ÉÇØÁö´Â °æ¿ì°¡ ÀÖ´Ù´Â ¸»¾¸ÀÔ´Ï´Ù. »ç½Ç ±×·± °æ¿ì´Â ÀûÁö ¾Ê½À´Ï´Ù. Á¶±âÀ§¾Ï °°°í ¼ö¼ú·Î ³¡³¯ °Í °°´Ù°í ¼³¸íÇÏ°í ¼ö¼úÇߴµ¥ ÁøÇ༺ À§¾ÏÀ¸·Î ³ª¿À°í Ç×¾ÏÄ¡·á±îÁö ¹Þ¾Æ¾ß Çϴ ȯÀÚµµ ±×·± °æ¿ìÀÔ´Ï´Ù.
¿ÜºÎ °ËÁø ³»½Ã°æ¿¡¼ cardiaÀÇ º´¼Ò°¡ ¹ß°ßµÇ¾ú°í Á¶Á÷°Ë»ç¿¡¼ high grade dysaplasia°¡ ³ª¿Í ÀǷڵǾú½À´Ï´Ù. ¿ÜºÎ ½½¶óÀ̵带 ÀçÆǵ¶ÇÑ °á°ú´Â tubular adenocarcinoma (W/D)¿´°í, º» º´¿ø¿¡¼ ³»½Ã°æ Àç°ËÇÑ °á°ú´Â tubular adenocarcinoma (M/D)¿´½À´Ï´Ù. 85% Á¤µµÀÇ Ãʱ⼺°ø·üÀ» ¿¹»óÇÑ´Ù°í ¼³¸íÇÏ°í ESD¸¦ ÇÏ¿´´Âµ¥ ¾Æ·¡ÀÇ °á°ú¿´½À´Ï´Ù.
Stomach, endoscopic submucosal dissection:
. Early gastric carcinoma
1. Location : cardia
2. Gross type : EGC type IIa+IIb
3. Histologic type : tubular adenocarcinoma, moderately differentiated (95%) >> signet ring cell carcinoma (5%)
4. Histologic type by Lauren : mixed
5. Size of carcinoma : (1) longest diameter, 24 mm (2) vertical diameter, 19 mm
6. Depth of invasion : invades submucosa, (depth of sm invasion : 1800 §) (pT1b)
7. Resection margin : deep resection margin involved by carcinoma with cauterized artifacts safety margin : distal 3 mm, proximal 2 mm, anterior 10 mm, posterior 2 mm, deep 0 mm (sm only)
8. Lymphatic invasion : present
9. Venous invasion : present
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: present
ESD º´¸® °á°ú ´Ù¼öÀÇ ¾È ÁÁÀº ¼Ò°ßÀÌ ÀÖ¾ú½À´Ï´Ù. (1) Signet ring cell carcinoma°¡ 5% ¼¯ÀÎ ¹ÌºÐÈ È¥Àç¾Ï, (2) deep SM invasion, (3) vertical resection margin involvement, (4) lymphovascular invasionÀÌ ±×°ÍÀÔ´Ï´Ù. ¼ö¼úÀ» ±ÇÇÏ¿´½À´Ï´Ù.
Stomach, radical total gastrectomy:
. Status post endoscopic submucosal dissection
. No residual tumor
1) Location: cannot be determined (no residual tumor)
2) Gross type: cannot be determined (no residual tumor)
3) Histologic type: cannot be determined (no residual tumor)
4) Histologic type by Lauren: cannot be determined (no residual tumor)
5) Size: cannot be determined (no residual tumor)
6) Depth of invasion: cannot be determined (no residual tumor)
7) Resection margin: free from carcinoma
8) Lymph node metastasis : no metastasis in 31 regional lymph nodes (pN0)
9) Lymphatic invasion: not identified
10) Venous invasion: not identified
11) Perineural invasion: not identified
12) Peritoneal cytology: negative
¾à°£ÀÇ ¿ì¿©°îÀýÀÌ ÀÖ¾úÁö¸¸ ÃÖÁ¾ ¼ö¼ú °á°ú¿¡¼ no residual tumor, no lymph node involvement¿´½À´Ï´Ù. ÀûÀýÇÑ ÀûÀÀÁõÀ¸·Î ESD¸¦ ½ÃÇàÇÑ ÈÄ ¼ö¼úÀÌ ÇÊ¿äÇÑ °á°ú°¡ ³ª¿ÔÀ» ¶§, ¼ö¼ú ÈÄ ÃÖÁ¾ º´¸®°á°ú¿¡¼ residual tumor³ª lymph node ÀüÀÌ°¡ È®ÀεǴ °æ¿ì´Â 10-20%ÀÔ´Ï´Ù (Kim ER. Br J Surg 2015).
ÀÌ È¯ÀÚ¸¦ óÀ½ºÎÅÍ ¼ö¼úÀ» ÇßÀ¸¸é ¾î¶°ÇÏ¿´À»±î, EUS¸¦ Çß´õ¶ó¸é ¾î¶°ÇÏ¿´À»±î Áú¹®ÀÌ °¡´ÉÇÒ °Í °°½À´Ï´Ù. ¹°·Ð EUS¿¡¼ SM invasionÀÌ ÀǽɵǴ °á°ú°¡ ³ª¿ÔÀ» ¼öµµ ÀÖÁö¸¸, EUS ¼Ò°ß¸¸À¸·Î óÀ½ºÎÅÍ total gastrectomy¸¦ ±ÇÇϱâ´Â ¾î·Á¿üÀ» °Í °°½À´Ï´Ù. Àú´Â ESD Àü EUS¸¦ °ÅÀÇ ÇÏÁö ¾Ê½À´Ï´Ù (EndoTODAY ESD Àü EUS´Â À¯¿ëÇÑ°¡? No). ¾Æ·¡´Â 2015³â Osaka ´ëÇп¡¼ ³»½Ã°æ°ú EUS¸¦ ÀûÀýÈ÷ »ç¿ëÇÏ´Â ¹æ¹ýÀ» Á¦¾ÈÇÑ algorithmÀÔ´Ï´Ù (Tsujii Y. GIE. 2015). "CE (conventional endoscopy) accurately revealed mucosal cancer, and EUS efficiently salvaged the lesions that were over-diagnosed by CE."¶ó°í ¾²°í ÀÖ½À´Ï´Ù. 'À§³»½Ã°æ¿¡¼ Á¡¸·ÇϾÏÀ¸·Î ÃßÁ¤µÇ´õ¶óµµ Ȥ½Ã Á¡¸·¾ÏÀÏ °¡´É¼ºÀÌ ÀÖÀ» ¶§¸¸ ¼±ÅÃÀûÀ¸·Î EUS¸¦ ½ÃÇàÇÏ¿© ȯÀÚ¿¡°Ô µµ¿òÀ» ÁØ´Ù'´Â ¾ÆÀ̵ð¾îÀÔ´Ï´Ù. ESD¸¦ °í·ÁÇÒ È¯ÀÚ¿¡¼´Â EUS°¡ ÇÊ¿äÇÏÁö ¾Ê°í, Á¡¸·ÇϾÏÀ¸·Î »ý°¢µÇ¾î ¼ö¼úÀ» °í·ÁÇÑ È¯ÀÚ¿¡¼´Â EUS¸¦ ÇØ º¸¾Æ¼ Á¡¸·¾Ïó·³ º¸À̸é ESD¸¦ ÇÏÀÚ´Â ¹æÇâÀÔ´Ï´Ù. Áï EUS¸¦ Çؼ ¼ö¼úÇÒ È¯ÀÚ¸¦ ESD ÇÏ´Â °æ¿ì´Â ÀÖÁö¸¸, ±× ¹Ý´ëÀÇ °æ¿ì(EUS °á°ú ÀÇ°Å ¼ö¼úÀ» ±ÇÇÔ)´Â ¾ø´Ù´Â °ÍÀÌ À̵éÀÇ Á¦¾ÈÀÔ´Ï´Ù. ±¹³»¿¡¼µµ À̵éÀÇ ¹æħ°ú °°Àº ÁÖÀåÀ» ÇÑ teamÀÌ ÀÖ½À´Ï´Ù. ÀüÀûÀ¸·Î µ¿ÀÇÇÕ´Ï´Ù.
ÀÌ Á¤µµÀÇ º´¼Ò´Â ÀÏ´Ü ESD¸¦ ÇÏ°í ÃÖÁ¾ º´¸®°á°ú¿¡ ÀÇÁ¸ÇÏ¿© Ãß°¡ Ä¡·á ¿©ºÎ¸¦ °áÁ¤ÇÏ´Â °ÍÀÌ ÀúÀÇ Áø·á styleÀ̸ç, ´ëºÎºÐÀÇ ESD Àü¹®°¡µéµµ ºñ½ÁÇÑ »ý°¢À» °¡Áö°í ÀÖ´Â °ÍÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ °ÍÀº ESD º´¸® °á°ú ¼ö¼úÀÌ ÇÊ¿äÇÏ´Ù°í ³ª¿À´Â °æ¿ì ¹Ýµå½Ã ¼ö¼úÀ» ¹ÞÀ¸¼Å¾ß ÇÑ´Ù´Â °ÍÀ» »çÀü¿¡ Àß ¼³¸íÇÏ´Â °ÍÀÔ´Ï´Ù. ´ÙÁü(ȤÀº °¢¼)À» ¹Þ¾ÆµÎ´Â °ÍÀÌ ÇÊ¿äÇÑ ÀÏÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ¼³¸íÇÏ°í, ¶Ç ¼³¸íÇÏ°í, ¶Ç ¼³¸íÇÏ°í, ¶Ç ¼³¸íÇÏ´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. Àú´Â º´¸®°á°ú¿¡ µû¶ó ¼ö¼úÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ 15%ÀÓÀ» ÃÖ¼ÒÇÑ 10¹ø ¼³¸íÇÏ°í ÀÖ½À´Ï´Ù. ù ¿Ü·¡¿¡¼ ¼³¸íÇÏ°í, °Ë»ç ÈÄ °á°úº¸·¯ ¿ÔÀ» ¶§ ¼³¸íÇÏ°í, ½Ã¼ú Àü ȸÁø ¶§ ¼³¸íÇÏ°í, ½Ã¼ú Á÷ÈÄ ³»½Ã°æ½Ç¿¡¼ ÀýÁ¦º´¼Ò¸¦ º¸¿©µå¸®¸é¼ ¼³¸íÇÏ°í, º´µ¿¿¡¼ ȸÁøµ¹ ¶§ ¼³¸íÇÏ°í, Åð¿ø Á÷Àü ´Ù½Ã Çѹø ¼³¸íÇÕ´Ï´Ù. °£È£ ÆÄÆ®¿¡¼µµ ÀÌ¿Í ºñ½ÁÇÏ°Ô ¿©·¯¹ø ¼³¸íÇÕ´Ï´Ù. ȯÀÚ ¾È³»¼¿¡µµ ¾º¿© ÀÖ°í, ȯÀÚ¿¡°Ô º¸¿©µå¸®´Â µ¿¿µ»ó¿¡¼µµ °Á¶µÇ¾î ÀÖ½À´Ï´Ù. ±×·¯´Ï... ÇÕÀÌ 10¹øÀ» Èǽ ³Ñ½À´Ï´Ù. ÀÌ Á¤µµ´Â µÇ¾î¾ß ȯÀÚ°¡ ¼ö¼úÀ» ¹Þ½À´Ï´Ù. ¼³¸íÀÌ ºÎÁ·ÇÑ »óÅ¿¡¼ ESD¸¦ ÇÏ°í ³ ÈÄ ¼ö¼úÀ» ±ÇÇϸé ȯÀÚ¿ÍÀÇ ¶øº¸°¡ ±Þ°ÝÈ÷ ±úÁý´Ï´Ù. ±Þ±â¾ß º´¿øÀ» ¿Å°Ü ¼ö¼ú¹Þ´Â ȯÀÚµµ ¹ß»ýÇÕ´Ï´Ù.
¿Ü·¡ ÀÚ·á. ¼ö¼ú°ú ³»½Ã°æ Ä¡·á Àå´ÜÁ¡ ºñ±³.
¿Ü·¡ ÀÚ·á. ¿¹»óº¸´Ù ±í°Å³ª ³ÐÀº °æ¿ì°¡ 15%-20%À̸ç, ÀÌ °æ¿ì "¼ö¼úÇÏ¼Å¾ß ÇÕ´Ï´Ù"¶ó°í °Á¶ÇÏ°í ÀÖ½À´Ï´Ù.
ÀÔ¿ø ȯÀÚ¿¡°Ô µå¸®¸é¼ ¼³¸íÇÏ´Â °³ÀÎ ¾È³»¼. 7¸í Áß 1¸íÀº ¼ö¼úÇØ¾ß ÇÔÀ» °Á¶ÇÏ°í ÀÖ½À´Ï´Ù.
ȯÀÚ ÀÔÀå¿¡¼´Â (1) óÀ½¿¡´Â dysplasia·Î ¼³¸íÀ» µé¾ú°í, (2) ´ÙÀ½¿¡´Â ¾ÏÀÌ´Ï 85% Á¤µµÀÇ Ãʱ⼺°ø·üÀ» ¿¹»óÇÏ´Â »óÅ¿¡¼ ESD¸¦ Çغ¸´Ù´Â Á¦¾ÈÀ» ¹Þ¾Ò°í, (3) °á±¹¿¡´Â total gastrectomy°¡ ÇÊ¿äÇÏ´Ù´Â ±ÇÀ¯¿¡ µû¶ó ¼ö¼úÀ» ¹Þ¾Ò½À´Ï´Ù. '°¥¼ö·Ï Å»ê'À̶ó´Â ¸»ÀÌ »ý°¢³³´Ï´Ù. °á°ú´Â ÁÁ¾Ò½À´Ï´Ù. Àú·Î¼´Â ÃÖ¼±ÀÇ ¼±ÅÃÀ̾ú´Ù°í ÆÇ´ÜÇÏ¿´½À´Ï´Ù.
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (2017-9-17)